Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AGN-190168 Formulation 1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AGN-190168 Formulation 1 | EXPERIMENTAL | AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days. |
| AGN-190168 Formulation 2 | EXPERIMENTAL | AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days. |
| TAZORAC® Gel 0.1% | ACTIVE_COMPARATOR | TAZORAC® Gel 0.1% (tazarotene gel 0.1%) applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days. |
| TAZORAC® Cream 0.1% | ACTIVE_COMPARATOR | TAZORAC® Cream 0.1% (tazarotene cream 0.1%) applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days. |
| Name | Type | Description |
|---|---|---|
| AGN-190168 Formulation 1 | DRUG | AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days. |
| AGN-190168 Formulation 2 | DRUG | AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days. |
| tazarotene gel 0.1% | DRUG | Tazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days. |
| tazarotene cream 0.1% | DRUG | Tazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days. |
Inclusion Criteria: * Diagnosis of acne vulgaris on the face * No tobacco use for the past 30 days, and willing to refrain from nicotine use during the study * Willing to avoid excessive or prolonged exposure of the treated skin to ultraviolet light (eg, sunlight, tanning beds) and extremes in weat...
AGN-190168 Formulation 1 is an investigational small molecule being developed for the treatment of acne vulgaris. It is in Phase 1 clinical development. The drug is being studied in patients with acne vulgaris, and it is not yet approved by regulatory authorities.
AGN-190168 Formulation 1 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The company is conducting clinical trials to evaluate the safety, tolerability, and pharmacokinetics of this investigational drug.
AGN-190168 Formulation 1 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The Phase 1 trial has been completed, and the drug remains in early-stage clinical development.
AGN-190168 Formulation 1 has one completed clinical trial, identified as NCT02218034. This Phase 1 study evaluated the safety, tolerability, and pharmacokinetics of the drug in 78 subjects with acne vulgaris in the United States. The trial was active-controlled and included participants aged 12 years and older.
AGN-190168 Formulation 1 is a specific formulation of the investigational drug AGN-190168. The clinical trial NCT02218034 refers to AGN-190168, and the formulation is being studied for the treatment of acne vulgaris. No other alternative names have been disclosed.